Market research future has a half-cooked research report on Global Ulcerative Colitis
Market. Global Ulcerative Colitis Market is growing rapidly and expected to continue its
growth by the end of 2022.
Market Highlights
The global Ulcerative colitis market has been evaluated as growing market and expected
that the market will reach high growth figures in the coming future. Ulcerative colitis is a
type of inflammatory bowel disease (IBD) that usually affects the lower section of body such
as sigmoid colon and the rectum. Belly pain or cramps, diarrhea and bleeding from the
rectum are some of the common symptoms of the diseases. According to CDC, the
worldwide incidence of ulcerative colitis is between 0.5 to 24.5 cases per 100,000 persons
per year. The reappearance of the disease’s symptoms is also high. According to Colitis
Foundation of America, about 30% of the people on remission are expected to suffer from
the disease flare-up in the future following the treatment and remission.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2354
Major factors leading to the growth of the market includes increasing prevalence of
ulcerative colitis, higher preference for symptomatic therapeutic, better treatment of
inflammatory bowel diseases, arrival of enhanced drugs and healthier investments in R&D
programs. Increasing patient pool with unmet needs, new drugs entering the market,
increasing global incidence & prevalence rate, and increasing investments towards research
in small molecules are some of the other factors leading the market growth. Blockbuster
drugs losing patent protection and growing the propensity for generic drugs are turning out
to be restraints for the market. The lack of curative therapy and personalized therapy and
medication are big opportunities for the market.
North America is expected to account for the largest share of the global Ulcerative colitis
Market in 2016, followed by Europe, the region will continue to lead the pack during the
forecast period. In Asia-Pacific, China leads the market. Economic development and
improvement of healthcare facilities are propelling the growth of the market. The entry of
Simponi and Entyvio is likely to petrol the growth of the market. However, Humira which
lost its patent in 2016 and Remicade, which will lose its patent in 2018 and will not have a
positive impact on the market.
Key Players:
Key players profiled in the report are Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical
Company Limited, and Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson &
Johnson Services, Inc., Ferring B.V., Janssen Biotech, and Merck
Segmentation: